937 results on '"A. Loupy"'
Search Results
2. Integrative multi-omics profiling in human decedents receiving pig heart xenografts
- Author
-
Schmauch, Eloi, Piening, Brian, Mohebnasab, Maedeh, Xia, Bo, Zhu, Chenchen, Stern, Jeffrey, Zhang, Weimin, Dowdell, Alexa K., Kim, Jacqueline I., Andrijevic, David, Khalil, Karen, Jaffe, Ian S., Loza, Bao-Li, Gragert, Loren, Camellato, Brendan R., Oliveira, Michelli F., O’Brien, Darragh P., Chen, Han M., Weldon, Elaina, Gao, Hui, Gandla, Divya, Chang, Andrew, Bhatt, Riyana, Gao, Sarah, Lin, Xiangping, Reddy, Kriyana P., Kagermazova, Larisa, Habara, Alawi H., Widawsky, Sophie, Liang, Feng-Xia, Sall, Joseph, Loupy, Alexandre, Heguy, Adriana, Taylor, Sarah E. B., Zhu, Yinan, Michael, Basil, Jiang, Lihua, Jian, Ruiqi, Chong, Anita S., Fairchild, Robert L., Linna-Kuosmanen, Suvi, Kaikkonen, Minna U., Tatapudi, Vasishta, Lorber, Marc, Ayares, David, Mangiola, Massimo, Narula, Navneet, Moazami, Nader, Pass, Harvey, Herati, Ramin S., Griesemer, Adam, Kellis, Manolis, Snyder, Michael P., Montgomery, Robert A., Boeke, Jef D., and Keating, Brendan J.
- Published
- 2024
- Full Text
- View/download PDF
3. Successful prevention of BK-polyomavirus nephropathy using extracorporeal photopheresis for immunosuppression minimisation following severe BK polyomavirus replication after kidney transplantation in a double lung transplant recipient, a case report
- Author
-
Von Tokarski, Florent, Parquin, François, Roux, Antoine, Hayem, Victor, Kerdiles, Thibault, Rabant, Marion, Isnard, Pierre, Loupy, Alexandre, Fourniol, Cyril, Tricot, Leila, Picard, Clément, Hertig, Alexandre, and Oniszczuk, Julie
- Published
- 2024
- Full Text
- View/download PDF
4. High-fat diet, microbiome-gut-brain axis signaling, and anxiety-like behavior in male rats
- Author
-
de Noronha, Sylvana I. S. Rendeiro, de Moraes, Lauro Angelo Gonçalves, Hassell, Jr., James E., Stamper, Christopher E., Arnold, Mathew R., Heinze, Jared D., Foxx, Christine L., Lieb, Margaret M., Cler, Kristin E., Karns, Bree L., Jaekel, Sophia, Loupy, Kelsey M., Silva, Fernanda C. S., Chianca-Jr., Deoclécio Alves, Lowry, Christopher A., and de Menezes, Rodrigo Cunha
- Published
- 2024
- Full Text
- View/download PDF
5. A Machine Learning-Driven Virtual Biopsy System For Kidney Transplant Patients
- Author
-
Yoo, Daniel, Divard, Gillian, Raynaud, Marc, Cohen, Aaron, Mone, Tom D., Rosenthal, John Thomas, Bentall, Andrew J., Stegall, Mark D., Naesens, Maarten, Zhang, Huanxi, Wang, Changxi, Gueguen, Juliette, Kamar, Nassim, Bouquegneau, Antoine, Batal, Ibrahim, Coley, Shana M., Gill, John S., Oppenheimer, Federico, De Sousa-Amorim, Erika, Kuypers, Dirk R. J., Durrbach, Antoine, Seron, Daniel, Rabant, Marion, Van Huyen, Jean-Paul Duong, Campbell, Patricia, Shojai, Soroush, Mengel, Michael, Bestard, Oriol, Basic-Jukic, Nikolina, Jurić, Ivana, Boor, Peter, Cornell, Lynn D., Alexander, Mariam P., Toby Coates, P., Legendre, Christophe, Reese, Peter P., Lefaucheur, Carmen, Aubert, Olivier, and Loupy, Alexandre
- Published
- 2024
- Full Text
- View/download PDF
6. From Humoral Theory to Performant Risk Stratification in Kidney Transplantation
- Author
-
C. Lefaucheur, D. Viglietti, M. Mangiola, A. Loupy, and A. Zeevi
- Subjects
Immunologic diseases. Allergy ,RC581-607 - Abstract
The purpose of the present review is to describe how we improve the model for risk stratification of transplant outcomes in kidney transplantation by incorporating the novel insights of donor-specific anti-HLA antibody (DSA) characteristics. The detection of anti-HLA DSA is widely used for the assessment of pre- and posttransplant risks of rejection and allograft loss; however, not all anti-HLA DSA carry the same risk for transplant outcomes. These antibodies have been shown to cause a wide spectrum of effects on allografts, ranging from the absence of injury to indolent or full-blown acute antibody-mediated rejection. Consequently, the presence of circulating anti-HLA DSA does not provide a sufficient level of accuracy for the risk stratification of allograft outcomes. Enhancing the predictive performance of anti-HLA DSA is currently one of the most pressing unmet needs for facilitating individualized treatment choices that may improve outcomes. Recent advancements in the assessment of anti-HLA DSA properties, including their strength, complement-binding capacity, and IgG subclass composition, significantly improved the risk stratification model to predict allograft injury and failure. Although risk stratification based on anti-HLA DSA properties appears promising, further specific studies that address immunological risk stratification in large and unselected populations are required to define the benefits and cost-effectiveness of such comprehensive assessment prior to clinical implementation.
- Published
- 2017
- Full Text
- View/download PDF
7. High-fat diet, microbiome-gut-brain axis signaling, and anxiety-like behavior in male rats
- Author
-
Sylvana I. S. Rendeiro de Noronha, Lauro Angelo Gonçalves de Moraes, James E. Hassell, Christopher E. Stamper, Mathew R. Arnold, Jared D. Heinze, Christine L. Foxx, Margaret M. Lieb, Kristin E. Cler, Bree L. Karns, Sophia Jaekel, Kelsey M. Loupy, Fernanda C. S. Silva, Deoclécio Alves Chianca-Jr., Christopher A. Lowry, and Rodrigo Cunha de Menezes
- Subjects
Anxiety ,Dorsal raphe nucleus ,High-fat diet ,Microbiome ,Microbiome-gut-brain axis ,Obesity ,Biology (General) ,QH301-705.5 - Abstract
Abstract Obesity, associated with the intake of a high-fat diet (HFD), and anxiety are common among those living in modern urban societies. Recent studies suggest a role of microbiome-gut-brain axis signaling, including a role for brain serotonergic systems in the relationship between HFD and anxiety. Evidence suggests the gut microbiome and the serotonergic brain system together may play an important role in this response. Here we conducted a nine-week HFD protocol in male rats, followed by an analysis of the gut microbiome diversity and community composition, brainstem serotonergic gene expression (tph2, htr1a, and slc6a4), and anxiety-related defensive behavioral responses. We show that HFD intake decreased alpha diversity and altered the community composition of the gut microbiome in association with obesity, increased brainstem tph2, htr1a and slc6a4 mRNA expression, including in the caudal part of the dorsomedial dorsal raphe nucleus (cDRD), a subregion previously associated with stress- and anxiety-related behavioral responses, and, finally, increased anxiety-related defensive behavioral responses. The HFD increased the Firmicutes/Bacteroidetes ratio relative to control diet, as well as higher relative abundances of Blautia, and decreases in Prevotella. We found that tph2, htr1a and slc6a4 mRNA expression were increased in subregions of the dorsal raphe nucleus in the HFD, relative to control diet. Specific bacterial taxa were associated with increased serotonergic gene expression in the cDRD. Thus, we propose that HFD-induced obesity is associated with altered microbiome-gut-serotonergic brain axis signaling, leading to increased anxiety-related defensive behavioral responses in rats.
- Published
- 2024
- Full Text
- View/download PDF
8. Banff Digital Pathology Working Group: Image Bank, Artificial Intelligence Algorithm, and Challenge Trial Developments.
- Author
-
Farris, Alton, Alexander, Mariam, Balis, Ulysses, Barisoni, Laura, Boor, Peter, Bülow, Roman, Cornell, Lynn, Demetris, Anthony, Farkash, Evan, Hermsen, Meyke, Hogan, Julien, Kain, Renate, Kers, Jesper, Kong, Jun, Levenson, Richard, Loupy, Alexandre, Naesens, Maarten, Sarder, Pinaki, Tomaszewski, John, van der Laak, Jeroen, van Midden, Dominique, Yagi, Yukako, and Solez, Kim
- Subjects
Banff ,artificial intelligence ,digital pathology ,image analysis ,machine learning ,Humans ,Artificial Intelligence ,Algorithms ,Kidney Transplantation ,Kidney - Abstract
The Banff Digital Pathology Working Group (DPWG) was established with the goal to establish a digital pathology repository; develop, validate, and share models for image analysis; and foster collaborations using regular videoconferencing. During the calls, a variety of artificial intelligence (AI)-based support systems for transplantation pathology were presented. Potential collaborations in a competition/trial on AI applied to kidney transplant specimens, including the DIAGGRAFT challenge (staining of biopsies at multiple institutions, pathologists visual assessment, and development and validation of new and pre-existing Banff scoring algorithms), were also discussed. To determine the next steps, a survey was conducted, primarily focusing on the feasibility of establishing a digital pathology repository and identifying potential hosts. Sixteen of the 35 respondents (46%) had access to a server hosting a digital pathology repository, with 2 respondents that could serve as a potential host at no cost to the DPWG. The 16 digital pathology repositories collected specimens from various organs, with the largest constituent being kidney (n = 12,870 specimens). A DPWG pilot digital pathology repository was established, and there are plans for a competition/trial with the DIAGGRAFT project. Utilizing existing resources and previously established models, the Banff DPWG is establishing new resources for the Banff community.
- Published
- 2023
9. Antibody Mediated Rejection and T-cell Mediated Rejection Molecular Signatures Using Next-Generation Sequencing in Kidney Transplant Biopsies
- Author
-
Esteban Cortes Garcia, Alessia Giarraputo, Maud Racapé, Valentin Goutaudier, Cindy Ursule-Dufait, Pierre de la Grange, Lucie Adoux, Marc Raynaud, Clément Couderau, Fariza Mezine, Jessie Dagobert, Oriol Bestard, Francesc Moreso, Jean Villard, Fabian Halleck, Magali Giral, Sophie Brouard, Richard Danger, Pierre-Antoine Gourraud, Marion Rabant, Lionel Couzi, Moglie Le Quintrec, Nassim Kamar, Emmanuel Morelon, François Vrtovsnik, Jean-Luc Taupin, Renaud Snanoudj, Christophe Legendre, Dany Anglicheau, Klemens Budde, Carmen Lefaucheur, Alexandre Loupy, and Olivier Aubert
- Subjects
next generation sequencing ,RNA-seq experiment ,kidney biopsies ,molecular signature ,allograft rejection ,kidney transplantation ,Specialties of internal medicine ,RC581-951 - Abstract
Recently, interest in transcriptomic assessment of kidney biopsies has been growing. This study investigates the use of NGS to identify gene expression changes and analyse the pathways involved in rejection. An Illumina bulk RNA sequencing on the polyadenylated RNA of 770 kidney biopsies was conducted. Differentially-expressed genes (DEGs) were determined for AMR and TCMR using DESeq2. Genes were segregated according to their previous descriptions in known panels (microarray or the Banff Human Organ Transplant (B-HOT) panel) to obtain NGS-specific genes. Pathway enrichment analysis was performed using the Reactome and Kyoto Encyclopaedia of Genes and Genomes (KEGG) public repositories. The differential gene expression using NGS analysis identified 6,141 and 8,478 transcripts associated with AMR and TCMR. While most of the genes identified were included in the microarray and the B-HOT panels, NGS analysis identified 603 (9.8%) and 1,186 (14%) new specific genes. Pathways analysis showed that the B-HOT panel was associated with the main immunological processes involved during AMR and TCMR. The microarrays specifically integrated metabolic functions and cell cycle progression processes. Novel NGS-specific based transcripts associated with AMR and TCMR were discovered, which might represent a novel source of targets for drug designing and repurposing.
- Published
- 2024
- Full Text
- View/download PDF
10. The role of donor hypertension and angiotensin II in the occurrence of early pancreas allograft thrombosis
- Author
-
Christophe Masset, Julien Branchereau, Fanny Buron, Georges Karam, Maud Rabeyrin, Karine Renaudin, Florent Le Borgne, Lionel Badet, Xavier Matillon, Christophe Legendre, Denis Glotz, Corinne Antoine, Magali Giral, Jacques Dantal, Diego Cantarovich, DIVAT Consortium, Maria Brunet, Rémi Cahen, Ricardo Codas, Sameh Daoud, Valérie Dubois, Coralie Fournie, Arnaud Grégoire, Alice Koenig, Charlène Lévi, Emmanuel Morelon, Claire Pouteil-Noble, Thomas Rimmelé, Olivier Thaunat, Gilles Blancho, Agnès Chapelet, Clément Deltombe, Lucile Figueres, Raphael Gaisne, Claire Garandeau, Caroline Gourraud-Vercel, Maryvonne Hourmant, Clarisse Kerleau, Delphine Kervella, Aurélie Meurette, Simon Ville, Christine Kandell, Anne Moreau, Florent Delbos, Alexandre Walencik, Anne Devis, Lucile Amrouche, Dany Anglicheau, Olivier Aubert, Lynda Bererhi, Alexandre Loupy, Frank Martinez, Arnaud Méjean, Rébecca Sberro-Soussan, Anne Scemla, Marc-Olivier Timsit, Julien Zuber, Gillian Divard, and Carmen Lefaucheur
- Subjects
body mass index (BMI) ,pre-procurement pancreas suitability score ,pancreas transplantation ,allograft thrombosis ,high blood pressure ,immunothrombosis ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundAbout 10–20% of pancreas allografts are still lost in the early postoperative period despite the identification of numerous detrimental risk factors that correlate with graft thrombosis.MethodsWe conducted a multicenter study including 899 pancreas transplant recipients between 2000 and 2018. Early pancreas failure due to complete thrombosis, long-term pancreas, kidney and patient survivals were analyzed and adjusted to donor, recipient and perioperative variables using a multivariate cause-specific Cox model stratified to transplant centers.ResultsPancreas from donors with history of hypertension (6.7%), as well as with high body mass index (BMI), were independently associated with an increased risk of pancreas failure within the first 30 post-operative days (respectively, HR= 2.57, 95% CI from 1.35 to 4.89 and HR= 1.11, 95% CI from 1.04 to 1.19). Interaction term between hypertension and BMI was negative. Donor hypertension also impacted long-term pancreas survival (HR= 1.88, 95% CI from 1.13 to 3.12). However, when pancreas survival was calculated after the postoperative day 30, donor hypertension was no longer a significant risk factor (HR= 1.22, 95% CI from 0.47 to 3.15). A lower pancreas survival was observed in patients receiving a pancreas from a hypertensive donor without RAAS (Renin Angiotensin Aldosterone System) blockers compared to others (50% vs 14%, p < 0.001). Pancreas survival was similar among non-hypertensive donors and hypertensive ones under RAAS blockers.ConclusionDonor hypertension was a significant and independent risk factor of pancreas failure. The well-known pathogenic role of renin-angiotensin-aldosterone system seems to be involved in the genesis of this immediate graft failure.
- Published
- 2024
- Full Text
- View/download PDF
11. Concepts and applications of digital twins in healthcare and medicine
- Author
-
Zhang, Kang, Zhou, Hong-Yu, Baptista-Hon, Daniel T., Gao, Yuanxu, Liu, Xiaohong, Oermann, Eric, Xu, Sheng, Jin, Shengwei, Zhang, Jian, Sun, Zhuo, Yin, Yun, Razmi, Ronald M., Loupy, Alexandre, Beck, Stephan, Qu, Jia, and Wu, Joseph
- Published
- 2024
- Full Text
- View/download PDF
12. A Machine Learning-Driven Virtual Biopsy System For Kidney Transplant Patients
- Author
-
Daniel Yoo, Gillian Divard, Marc Raynaud, Aaron Cohen, Tom D. Mone, John Thomas Rosenthal, Andrew J. Bentall, Mark D. Stegall, Maarten Naesens, Huanxi Zhang, Changxi Wang, Juliette Gueguen, Nassim Kamar, Antoine Bouquegneau, Ibrahim Batal, Shana M. Coley, John S. Gill, Federico Oppenheimer, Erika De Sousa-Amorim, Dirk R. J. Kuypers, Antoine Durrbach, Daniel Seron, Marion Rabant, Jean-Paul Duong Van Huyen, Patricia Campbell, Soroush Shojai, Michael Mengel, Oriol Bestard, Nikolina Basic-Jukic, Ivana Jurić, Peter Boor, Lynn D. Cornell, Mariam P. Alexander, P. Toby Coates, Christophe Legendre, Peter P. Reese, Carmen Lefaucheur, Olivier Aubert, and Alexandre Loupy
- Subjects
Science - Abstract
Abstract In kidney transplantation, day-zero biopsies are used to assess organ quality and discriminate between donor-inherited lesions and those acquired post-transplantation. However, many centers do not perform such biopsies since they are invasive, costly and may delay the transplant procedure. We aim to generate a non-invasive virtual biopsy system using routinely collected donor parameters. Using 14,032 day-zero kidney biopsies from 17 international centers, we develop a virtual biopsy system. 11 basic donor parameters are used to predict four Banff kidney lesions: arteriosclerosis, arteriolar hyalinosis, interstitial fibrosis and tubular atrophy, and the percentage of renal sclerotic glomeruli. Six machine learning models are aggregated into an ensemble model. The virtual biopsy system shows good performance in the internal and external validation sets. We confirm the generalizability of the system in various scenarios. This system could assist physicians in assessing organ quality, optimizing allograft allocation together with discriminating between donor derived and acquired lesions post-transplantation.
- Published
- 2024
- Full Text
- View/download PDF
13. An automated histological classification system for precision diagnostics of kidney allografts
- Author
-
Yoo, Daniel, Goutaudier, Valentin, Divard, Gillian, Gueguen, Juliette, Astor, Brad C., Aubert, Olivier, Raynaud, Marc, Demir, Zeynep, Hogan, Julien, Weng, Patricia, Smith, Jodi, Garro, Rouba, Warady, Bradley A., Zahr, Rima S., Sablik, Marta, Twombley, Katherine, Couzi, Lionel, Berney, Thierry, Boyer, Olivia, Duong-Van-Huyen, Jean-Paul, Giral, Magali, Alsadi, Alaa, Gourraud, Pierre A., Morelon, Emmanuel, Le Quintrec, Moglie, Brouard, Sophie, Legendre, Christophe, Anglicheau, Dany, Villard, Jean, Zhong, Weixiong, Kamar, Nassim, Bestard, Oriol, Djamali, Arjang, Budde, Klemens, Haas, Mark, Lefaucheur, Carmen, Rabant, Marion, and Loupy, Alexandre
- Published
- 2023
- Full Text
- View/download PDF
14. Banff Digital Pathology Working Group: Image Bank, Artificial Intelligence Algorithm, and Challenge Trial Developments
- Author
-
Alton B. Farris, Mariam P. Alexander, Ulysses G. J. Balis, Laura Barisoni, Peter Boor, Roman D. Bülow, Lynn D. Cornell, Anthony J. Demetris, Evan Farkash, Meyke Hermsen, Julien Hogan, Renate Kain, Jesper Kers, Jun Kong, Richard M. Levenson, Alexandre Loupy, Maarten Naesens, Pinaki Sarder, John E. Tomaszewski, Jeroen van der Laak, Dominique van Midden, Yukako Yagi, and Kim Solez
- Subjects
Banff ,digital pathology ,artificial intelligence ,machine learning ,image analysis ,Specialties of internal medicine ,RC581-951 - Abstract
The Banff Digital Pathology Working Group (DPWG) was established with the goal to establish a digital pathology repository; develop, validate, and share models for image analysis; and foster collaborations using regular videoconferencing. During the calls, a variety of artificial intelligence (AI)-based support systems for transplantation pathology were presented. Potential collaborations in a competition/trial on AI applied to kidney transplant specimens, including the DIAGGRAFT challenge (staining of biopsies at multiple institutions, pathologists’ visual assessment, and development and validation of new and pre-existing Banff scoring algorithms), were also discussed. To determine the next steps, a survey was conducted, primarily focusing on the feasibility of establishing a digital pathology repository and identifying potential hosts. Sixteen of the 35 respondents (46%) had access to a server hosting a digital pathology repository, with 2 respondents that could serve as a potential host at no cost to the DPWG. The 16 digital pathology repositories collected specimens from various organs, with the largest constituent being kidney (n = 12,870 specimens). A DPWG pilot digital pathology repository was established, and there are plans for a competition/trial with the DIAGGRAFT project. Utilizing existing resources and previously established models, the Banff DPWG is establishing new resources for the Banff community.
- Published
- 2023
- Full Text
- View/download PDF
15. Complement-activating donor-specific anti-HLA antibodies in solid organ transplantation: systematic review, meta-analysis, and critical appraisal
- Author
-
Solaf Al-Awadhi, Marc Raynaud, Kevin Louis, Antoine Bouquegneau, Jean-Luc Taupin, Olivier Aubert, Alexandre Loupy, and Carmen Lefaucheur
- Subjects
complement-activation ,donor specific antibodies ,anti-HLA ,rejection ,transplantation outcomes ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionSeveral studies have investigated the impact of circulating complement-activating anti-human leukocyte antigen donor-specific antibodies (anti-HLA DSAs) on organ transplant outcomes. However, a critical appraisal of these studies and a demonstration of the prognostic value of complement-activating status over anti-HLA DSA mean fluorescence intensity (MFI) level are lacking.MethodsWe conducted a systematic review, meta-analysis and critical appraisal evaluating the role of complement-activating anti-HLA DSAs on allograft outcomes in different solid organ transplants. We included studies through Medline, Cochrane, Scopus, and Embase since inception of databases till May 05, 2023. We evaluated allograft loss as the primary outcome, and allograft rejection as the secondary outcome. We used the Newcastle-Ottawa Scale and funnel plots to assess risk of bias and used bias adjustment methods when appropriate. We performed multiple subgroup analyses to account for sources of heterogeneity and studied the added value of complement assays over anti-HLA DSA MFI level.ResultsIn total, 52 studies were included in the final meta-analysis (11,035 patients). Complement-activating anti-HLA DSAs were associated with an increased risk of allograft loss (HR 2.77; 95% CI 2.33-3.29, p
- Published
- 2023
- Full Text
- View/download PDF
16. Qualifying a Novel Clinical Trial Endpoint (iBOX) Predictive of Long-Term Kidney Transplant Outcomes
- Author
-
Amanda Klein, Alexandre Loupy, Mark Stegall, Ilkka Helanterä, Luke Kosinski, Eric Frey, Olivier Aubert, Gillian Divard, Kenneth Newell, Herwig-Ulf Meier-Kriesche, Roslyn Mannon, Thomas Dumortier, Varun Aggarwal, Jagdeep T. Podichetty, Inish O’Doherty, Ahmed Osama Gaber, and William E. Fitzsimmons
- Subjects
kidney transplant ,iBox ,transplant outcomes ,organ transplant ,transplant clinical trial ,Specialties of internal medicine ,RC581-951 - Abstract
New immunosuppressive therapies that improve long-term graft survival are needed in kidney transplant. Critical Path Institute’s Transplant Therapeutics Consortium received a qualification opinion for the iBOX Scoring System as a novel secondary efficacy endpoint for kidney transplant clinical trials through European Medicines Agency’s qualification of novel methodologies for drug development. This is the first qualified endpoint for any transplant indication and is now available for use in kidney transplant clinical trials. Although the current efficacy failure endpoint has typically shown the noninferiority of therapeutic regimens, the iBOX Scoring System can be used to demonstrate the superiority of a new immunosuppressive therapy compared to the standard of care from 6 months to 24 months posttransplant in pivotal or exploratory drug therapeutic studies.
- Published
- 2023
- Full Text
- View/download PDF
17. Comparison of artificial intelligence and human-based prediction and stratification of the risk of long-term kidney allograft failure
- Author
-
Gillian Divard, Marc Raynaud, Vasishta S. Tatapudi, Basmah Abdalla, Elodie Bailly, Maureen Assayag, Yannick Binois, Raphael Cohen, Huanxi Zhang, Camillo Ulloa, Kamila Linhares, Helio S. Tedesco, Christophe Legendre, Xavier Jouven, Robert A. Montgomery, Carmen Lefaucheur, Olivier Aubert, and Alexandre Loupy
- Subjects
Medicine - Abstract
Divard, Raynaud et al. compare artificial intelligence (AI)-based predictions of kidney allograft failure based on electronic health records with those made by transplant physicians of varying levels of experience. The ability of physicians to predict allograft failure is limited, with superior performance seen for the AI system.
- Published
- 2022
- Full Text
- View/download PDF
18. Immunosuppressant drugs and quality-of-life outcomes in kidney transplant recipients: An international cohort study (EU-TRAIN)
- Author
-
François R. Girardin, Anna Nicolet, Oriol Bestard, Carmen Lefaucheur, Klemens Budde, Fabian Halleck, Sophie Brouard, Magali Giral, Pierre-Antoine Gourraud, Béatrice Horcholle, Jean Villard, Joachim Marti, and Alexandre Loupy
- Subjects
immunosuppressant ,kidney transplant patient ,quality of life ,PROMS ,VAS (analog visual scale) ,EQ5D 3L ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Introduction: Patient-Reported Outcomes (PRO) integrate a wide range of holistic dimensions that arenot captured within clinical outcomes. Particularly, from induction treatment to maintenance therapy, patient quality-of-life (QoL) of kidney transplant recipients have been sparsely investigated in international settings.Methods: In a prospective, multi-centric cohort study, including nine transplant centers in four countries, we explored the QoL during the year following transplantation using validated elicitation instruments (EQ-5D-3L index with VAS) in a population of kidney transplant patients receiving immunosuppressive therapies. Calcineurin inhibitors (tacrolimus and ciclosporin), IMPD inhibitor (mycophenolate mofetil), and mTOR inhibitors (everolimus and sirolimus) were the standard-of-care (SOC) medications, together with tapering glucocorticoid therapy. We used EQ-5D and VAS data as QoL measures alongside descriptive statistics at inclusion, per country and hospital center. We computed the proportions of patients with different immunosuppressive therapy patterns, and using bivariate and multivariate analyses, assessed the variations of EQ-5D and VAS between baseline (i.e., inclusion Month 0) and follow up visits (Month 12).Results: Among 542 kidney transplant patients included and followed from November 2018 to June 2021, 491 filled at least one QoL questionnaire at least at baseline (Month 0). The majority of patients in all countries received tacrolimus and mycophenolate mofetil, ranging from 90.0% in Switzerland and Spain to 95.8% in Germany. At M12, a significant proportion of patients switched immunosuppressive drugs, with proportion varying from 20% in Germany to 40% in Spain and Switzerland. At visit M12, patients who kept SOC therapy had higher EQ-5D (by 8 percentage points, p < 0.05) and VAS (by 4 percentage points, p < 0.1) scores than switchers. VAS scores were generally lower than EQ-5D (mean 0.68 [0.5–0.8] vs. 0.85 [0.8–1]).Discussion: Although overall a positive trend in QoL was observed, the formal analyses did not show any significant improvements in EQ-5D scores or VAS. Only when the effect of a therapy use was separated from the effect of switching, the VAS score was significantly worse for switchers during the follow up period, irrespective of the therapy type. If adjusted for patient characteristics and medical history (e.g., gender, BMI, eGRF, history of diabetes), VAS and EQ-5D delivered sound PRO measures for QoL assessments during the year following renal transplantation.
- Published
- 2023
- Full Text
- View/download PDF
19. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial
- Author
-
Mayer, Katharina A., Budde, Klemens, Halloran, Philip F., Doberer, Konstantin, Rostaing, Lionel, Eskandary, Farsad, Christamentl, Anna, Wahrmann, Markus, Regele, Heinz, Schranz, Sabine, Ely, Sarah, Firbas, Christa, Schörgenhofer, Christian, Kainz, Alexander, Loupy, Alexandre, Härtle, Stefan, Boxhammer, Rainer, Jilma, Bernd, and Böhmig, Georg A.
- Published
- 2022
- Full Text
- View/download PDF
20. Comparison of artificial intelligence and human-based prediction and stratification of the risk of long-term kidney allograft failure
- Author
-
Divard, Gillian, Raynaud, Marc, Tatapudi, Vasishta S., Abdalla, Basmah, Bailly, Elodie, Assayag, Maureen, Binois, Yannick, Cohen, Raphael, Zhang, Huanxi, Ulloa, Camillo, Linhares, Kamila, Tedesco, Helio S., Legendre, Christophe, Jouven, Xavier, Montgomery, Robert A., Lefaucheur, Carmen, Aubert, Olivier, and Loupy, Alexandre
- Published
- 2022
- Full Text
- View/download PDF
21. Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial
- Author
-
Katharina A. Mayer, Klemens Budde, Philip F. Halloran, Konstantin Doberer, Lionel Rostaing, Farsad Eskandary, Anna Christamentl, Markus Wahrmann, Heinz Regele, Sabine Schranz, Sarah Ely, Christa Firbas, Christian Schörgenhofer, Alexander Kainz, Alexandre Loupy, Stefan Härtle, Rainer Boxhammer, Bernd Jilma, and Georg A. Böhmig
- Subjects
Antibody-mediated rejection ,CD38 ,Donor-specific antibody ,Felzartamab ,Kidney transplantation ,Monoclonal antibody ,Medicine (General) ,R5-920 - Abstract
Abstract Background Antibody-mediated rejection (ABMR) is a cardinal cause of renal allograft loss. This rejection type, which may occur at any time after transplantation, commonly presents as a continuum of microvascular inflammation (MVI) culminating in chronic tissue injury. While the clinical relevance of ABMR is well recognized, its treatment, particularly a long time after transplantation, has remained a big challenge. A promising strategy to counteract ABMR may be the use of CD38-directed treatment to deplete alloantibody-producing plasma cells (PC) and natural killer (NK) cells. Methods This investigator-initiated trial is planned as a randomized, placebo-controlled, double-blind, parallel-group, multi-center phase 2 trial designed to assess the safety and tolerability (primary endpoint), pharmacokinetics, immunogenicity, and efficacy of the fully human CD38 monoclonal antibody felzartamab (MOR202) in late ABMR. The trial will include 20 anti-HLA donor-specific antibody (DSA)-positive renal allograft recipients diagnosed with active or chronic active ABMR ≥ 180 days post-transplantation. Subjects will be randomized 1:1 to receive felzartamab (16 mg/kg per infusion) or placebo for a period of 6 months (intravenous administration on day 0, and after 1, 2, 3, 4, 8, 12, 16, and 20 weeks). Two follow-up allograft biopsies will be performed at weeks 24 and 52. Secondary endpoints (preliminary assessment) will include morphologic and molecular rejection activity in renal biopsies, immunologic biomarkers in the blood and urine, and surrogate parameters predicting the progression to allograft failure (slope of renal function; iBOX prediction score). Discussion Based on the hypothesis that felzartamab is able to halt the progression of ABMR via targeting antibody-producing PC and NK cells, we believe that our trial could potentially provide the first proof of concept of a new treatment in ABMR based on a prospective randomized clinical trial. Trial registration EU Clinical Trials Register (EudraCT) 2021-000545-40 . Registered on 23 June 2021. ClinicalTrials.gov NCT05021484 . Registered on 25 August 2021
- Published
- 2022
- Full Text
- View/download PDF
22. High fidelity, multi-disciplinary analysis of flow in realistic weapon bays
- Author
-
Loupy, Gaëtan J. M.
- Subjects
629.13 ,TA Engineering (General). Civil engineering (General) ,TL Motor vehicles. Aeronautics. Astronautics ,U Military Science (General) - Abstract
To improve the stealthiness, and the efficiency of military aircraft, engineers moved carried weapons from external hand points, to weapons bays. However, the flow inside bays is turbulent, and characterised by strong broadband, and tonal noise. The open bay flow leads to variability in the released store trajectory, excites the missile, and bay structures, and reduces the aircraft stealthiness. This thesis aims to improve our understanding of real weapon bay flow, and suggests a method for quantifying the store trajectory variability. The main spatio-temporal characteristics of cavity flows are described using post-processing methods, like, SPL, OASPL, and wavelet transform. Also, the code HMB3 is validated for simulation of cavity flows, comparing Scale Adaptive (SAS) results with experiments. To further improve the understanding of the physics driving this flow, a simple model is presented, and compared to experiments. The results are promising, and the model is able to reproduce the cavity flow fluctuations both in space and time. To support measurements of the noise field around a cavity flow, beamforming is applied to the CFD results. This method was able of capturing the main sources of noise around the cavity, using a microphone array, and the mean flow to simulate the propagation of acoustic waves. Also, recommendations for future use of this technique are given. Developments were carried out for this thesis, and for the first time, a CFD code is reported to simulate the complete weapon bay operation, including door operation, store release, and store aeroelasticity. The different parts of the code are strongly coupled, and work together. Thanks to new capabilities of HMB3, this thesis shows more insight on the physics behind realistic weapon bay operation. The flow establishment during door opening is described, and appears to be important for store design, only if the doors are moving very fast. Store releases are simulated, and statistical analysis of the data is performed. A statistical metric was proposed to identify the minimum number of simulations necessary for capturing the mean and standard deviation of the trajectories. Using averaged, and filtered flow data, the trajectory phases were identified and the role of the pressure field inside the cavity was clarified. In addition, the aeroelasticity of the store was computed during carriage, door opening, and release phases, showing small deformations that may lead to structural fatigue. Thanks to the efficiency of the SAS method, a large number of simulations were performed, and more than 1800 cavity travel times were simulated. Simulation of the flow around a store in a supersonic flow, and at high attitude is described in an appendix of the thesis. Like a cavity, this flow has complex features that require advanced turbulence modelling to be simulated. In addition, novel cavity flow controls are investigated, and described in a restricted appendix of the thesis.
- Published
- 2018
23. Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.
- Author
-
Bouquegneau, Antoine, Loheac, Charlotte, Aubert, Olivier, Bouatou, Yassine, Viglietti, Denis, Empana, Jean-Philippe, Ulloa, Camilo, Murad, Mohammad Hassan, Legendre, Christophe, Glotz, Denis, Jackson, Annette M, Zeevi, Adriana, Schaub, Stephan, Taupin, Jean-Luc, Reed, Elaine F, Friedewald, John J, Tyan, Dolly B, Süsal, Caner, Shapiro, Ron, Woodle, E Steve, Hidalgo, Luis G, O'Leary, Jacqueline, Montgomery, Robert A, Kobashigawa, Jon, Jouven, Xavier, Jabre, Patricia, Lefaucheur, Carmen, and Loupy, Alexandre
- Subjects
Humans ,Antibodies ,HLA Antigens ,Complement Activation ,Transplantation Immunology ,Graft Rejection ,Graft Survival ,General & Internal Medicine ,Medical and Health Sciences - Abstract
BACKGROUND:Anti-human leukocyte antigen donor-specific antibodies (anti-HLA DSAs) are recognized as a major barrier to patients' access to organ transplantation and the major cause of graft failure. The capacity of circulating anti-HLA DSAs to activate complement has been suggested as a potential biomarker for optimizing graft allocation and improving the rate of successful transplantations. METHODS AND FINDINGS:To address the clinical relevance of complement-activating anti-HLA DSAs across all solid organ transplant patients, we performed a meta-analysis of their association with transplant outcome through a systematic review, from inception to January 31, 2018. The primary outcome was allograft loss, and the secondary outcome was allograft rejection. A comprehensive search strategy was conducted through several databases (Medline, Embase, Cochrane, and Scopus). A total of 5,861 eligible citations were identified. A total of 37 studies were included in the meta-analysis. Studies reported on 7,936 patients, including kidney (n = 5,991), liver (n = 1,459), heart (n = 370), and lung recipients (n = 116). Solid organ transplant recipients with circulating complement-activating anti-HLA DSAs experienced an increased risk of allograft loss (pooled HR 3.09; 95% CI 2.55-3.74, P = 0.001; I2 = 29.3%), and allograft rejection (pooled HR 3.75; 95% CI: 2.05-6.87, P = 0.001; I2 = 69.8%) compared to patients without complement-activating anti-HLA DSAs. The association between circulating complement-activating anti-HLA DSAs and allograft failure was consistent across all subgroups and sensitivity analyses. Limitations of the study are the observational and retrospective design of almost all included studies, the higher proportion of kidney recipients compared to other solid organ transplant recipients, and the inclusion of fewer studies investigating allograft rejection. CONCLUSIONS:In this study, we found that circulating complement-activating anti-HLA DSAs had a significant deleterious impact on solid organ transplant survival and risk of rejection. The detection of complement-activating anti-HLA DSAs may add value at an individual patient level for noninvasive biomarker-guided risk stratification. TRIAL REGISTRATION:National Clinical Trial protocol ID: NCT03438058.
- Published
- 2018
24. Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study
- Author
-
Raynaud, Marc, Aubert, Olivier, Divard, Gillian, Reese, Peter P, Kamar, Nassim, Yoo, Daniel, Chin, Chen-Shan, Bailly, Élodie, Buchler, Matthias, Ladrière, Marc, Le Quintrec, Moglie, Delahousse, Michel, Juric, Ivana, Basic-Jukic, Nikolina, Crespo, Marta, Silva, Helio Tedesco, Jr, Linhares, Kamilla, Ribeiro de Castro, Maria Cristina, Soler Pujol, Gervasio, Empana, Jean-Philippe, Ulloa, Camilo, Akalin, Enver, Böhmig, Georg, Huang, Edmund, Stegall, Mark D, Bentall, Andrew J, Montgomery, Robert A, Jordan, Stanley C, Oberbauer, Rainer, Segev, Dorry L, Friedewald, John J, Jouven, Xavier, Legendre, Christophe, Lefaucheur, Carmen, and Loupy, Alexandre
- Published
- 2021
- Full Text
- View/download PDF
25. COVID-19 pandemic and worldwide organ transplantation: a population-based study
- Author
-
Aubert, Olivier, Yoo, Daniel, Zielinski, Dina, Cozzi, Emanuele, Cardillo, Massimo, Dürr, Michael, Domínguez-Gil, Beatriz, Coll, Elisabeth, Da Silva, Margarida Ivo, Sallinen, Ville, Lemström, Karl, Midtvedt, Karsten, Ulloa, Camilo, Immer, Franz, Weissenbacher, Annemarie, Vallant, Natalie, Basic-Jukic, Nikolina, Tanabe, Kazunari, Papatheodoridis, Georgios, Menoudakou, Georgia, Torres, Martin, Soratti, Carlos, Hansen Krogh, Daniela, Lefaucheur, Carmen, Ferreira, Gustavo, Silva, Helio Tedesco, Jr, Hartell, David, Forsythe, John, Mumford, Lisa, Reese, Peter P, Kerbaul, François, Jacquelinet, Christian, Vogelaar, Serge, Papalois, Vassilios, and Loupy, Alexandre
- Published
- 2021
- Full Text
- View/download PDF
26. The emerging field of non–human leukocyte antigen antibodies in transplant medicine and beyond
- Author
-
Lefaucheur, Carmen, Louis, Kevin, Philippe, Aurélie, Loupy, Alexandre, and Coates, P. Toby
- Published
- 2021
- Full Text
- View/download PDF
27. Abstract 13280: Proteomic Indicators of Cardiovascular Health Relate to Brain Volume and Dementia Risk
- Author
-
Dark, Heather E, Paterson, Clare, Peng, Zhongsheng, Duggan, Michael R, Daya, Gulzar N, Bilgel, Murat, An, Yang, Moghekar, Abhay, Davatzikos, Christos, Resnick, Susan, Loupy, Kelsey, Simpson, Missy, Mosley, Thomas, Coresh, Josef, Williams, Stephen A, and Walker, Keenan A
- Published
- 2022
- Full Text
- View/download PDF
28. Complement inhibition for prevention of antibody-mediated rejection in immunologically high-risk heart allograft recipients
- Author
-
Patel, Jignesh K., Coutance, Guillaume, Loupy, Alexandre, Dilibero, Deanna, Hamilton, Michele, Kittleson, Michelle, Kransdorf, Evan, Azarbal, Babak, Seguchi, Osamu, Zhang, Xiaohai, Chang, David, Geft, Dael, Czer, Lawrence, Varnous, Shaida, and Kobashigawa, Jon A.
- Published
- 2021
- Full Text
- View/download PDF
29. Time-dependent lymphocyte count after transplantation is associated with higher risk of graft failure and death
- Author
-
Blancho, Gilles, Branchereau, Julien, Cantarovich, Diego, Chapelet, Agnès, Dantal, Jacques, Deltombe, Clément, Figueres, Lucile, Garandeau, Claire, Giral, Magali, Gourraud-Vercel, Caroline, Hourmant, Maryvonne, Karam, Georges, Kerleau, Clarisse, Meurette, Aurélie, Ville, Simon, Kandell, Christine, Moreau, Anne, Renaudin, Karine, Cesbron, Anne, Delbos, Florent, Walencik, Alexandre, Devis, Anne, Amrouche, Lucile, Anglicheau, Dany, Aubert, Olivier, Bererhi, Lynda, Legendre, Christophe, Loupy, Alexandre, Martinez, Frank, Sberro-Soussan, Rébecca, Scemla, Anne, Tinel, Claire, Zuber, Julien, Dujardin, Amaury, Lorent, Marine, Foucher, Yohann, and Brouard, Sophie
- Published
- 2021
- Full Text
- View/download PDF
30. Statistical performance of 16 posttransplant risk scores in a contemporary cohort of heart transplant recipients
- Author
-
Coutance, Guillaume, Kransdorf, Evan, Bonnet, Guillaume, Loupy, Alexandre, Kobashigawa, Jon, and Patel, Jignesh K.
- Published
- 2021
- Full Text
- View/download PDF
31. The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions
- Author
-
Bruneval, P, Angelini, A, Miller, D, Potena, L, Loupy, A, Zeevi, A, Reed, EF, Dragun, D, Reinsmoen, N, Smith, RN, West, L, Tebutt, S, Thum, T, Haas, M, Mengel, M, Revelo, P, Fedrigo, M, Van Huyen, JP Duong, and Berry, GJ
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Cardiovascular ,Heart Disease ,Transplantation ,Organ Transplantation ,Graft Rejection ,Humans ,Isoantibodies ,Practice Guidelines as Topic ,Research Report ,Transplantation ,Homologous ,clinical research ,practice ,heart transplantation ,cardiology ,rejection ,rejection: antibody-mediated ,rejection: subclinical ,translational research ,science ,clinical research/practice ,heart transplantation/cardiology ,translational research/science ,Medical and Health Sciences ,Surgery ,Clinical sciences ,Immunology - Abstract
The 13th Banff Conference on Allograft Pathology was held in Vancouver, British Columbia, Canada from October 5 to 10, 2015. The cardiac session was devoted to current diagnostic issues in heart transplantation with a focus on antibody-mediated rejection (AMR) and small vessel arteriopathy. Specific topics included the strengths and limitations of the current rejection grading system, the central role of microvascular injury in AMR and approaches to semiquantitative assessment of histopathologic and immunophenotypic indicators, the role of AMR in the development of cardiac allograft vasculopathy, the important role of serologic antibody detection in the management of transplant recipients, and the potential application of new molecular approaches to the elucidation of the pathophysiology of AMR and potential for improving the current diagnostic system. Herein we summarize the key points from the presentations, the comprehensive, open and wide-ranging multidisciplinary discussion that was generated, and considerations for future endeavors.
- Published
- 2017
32. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology
- Author
-
Loupy, A, Haas, M, Solez, K, Racusen, L, Glotz, D, Seron, D, Nankivell, BJ, Colvin, RB, Afrouzian, M, Akalin, E, Alachkar, N, Bagnasco, S, Becker, JU, Cornell, L, Drachenberg, C, Dragun, D, de Kort, H, Gibson, IW, Kraus, ES, Lefaucheur, C, Legendre, C, Liapis, H, Muthukumar, T, Nickeleit, V, Orandi, B, Park, W, Rabant, M, Randhawa, P, Reed, EF, Roufosse, C, Seshan, SV, Sis, B, Singh, HK, Schinstock, C, Tambur, A, Zeevi, A, and Mengel, M
- Subjects
Organ Transplantation ,Clinical Research ,Transplantation ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Renal and urogenital ,Arteritis ,Complement C4b ,Graft Rejection ,Humans ,Isoantibodies ,Kidney Transplantation ,Peptide Fragments ,Research Report ,clinical research ,practice ,translational research ,science ,kidney transplantation ,nephrology ,pathology ,histopathology ,organ transplantation in general ,rejection ,rejection: antibody-mediated ,rejection: subclinical ,rejection: T cell mediated ,clinical research/practice ,kidney transplantation/nephrology ,pathology/histopathology ,translational research/science ,Medical and Health Sciences ,Surgery - Abstract
The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i-IFTA score, comprising inflammation within areas of fibrosis and atrophy and acceptance of transplant arteriolopathy within the descriptions of chronic active T cell-mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histologic, serologic, and molecular diagnostic techniques to produce a consensus-based reporting system that offers precise composite scores, accurate routine diagnostics, and applicability to next-generation clinical trials.
- Published
- 2017
33. Trajectories of glomerular filtration rate and progression to end stage kidney disease after kidney transplantation
- Author
-
Raynaud, Marc, Aubert, Olivier, Reese, Peter P., Bouatou, Yassine, Naesens, Maarten, Kamar, Nassim, Bailly, Élodie, Giral, Magali, Ladrière, Marc, Le Quintrec, Moglie, Delahousse, Michel, Juric, Ivana, Basic-Jukic, Nikolina, Gupta, Gaurav, Akalin, Enver, Yoo, Daniel, Chin, Chen-Shan, Proust-Lima, Cécile, Böhmig, Georg, Oberbauer, Rainer, Stegall, Mark D., Bentall, Andrew J., Jordan, Stanley C., Huang, Edmund, Glotz, Denis, Legendre, Christophe, Montgomery, Robert A., Segev, Dorry L., Empana, Jean-Philippe, Grams, Morgan E., Coresh, Josef, Jouven, Xavier, Lefaucheur, Carmen, and Loupy, Alexandre
- Published
- 2021
- Full Text
- View/download PDF
34. The Banff 2022 Kidney Meeting Work Plan:Data-driven refinement of the Banff Classification for renal allografts
- Author
-
Roufosse, Candice, Naesens, Maarten, Haas, Mark, Lefaucheur, Carmen, Mannon, Roslyn B., Afrouzian, Marjan, Alachkar, Nada, Aubert, Olivier, Bagnasco, Serena M., Batal, Ibrahim, Bellamy, Chris O.C., Broecker, Verena, Budde, Klemens, Clahsen-Van Groningen, Marian, Coley, Shana M., Cornell, Lynn D., Dadhania, Darshana, Demetris, Anthony J., Einecke, Gunilla, Farris, Alton B., Fogo, Agnes B., Friedewald, John, Gibson, Ian W., Horsfield, Catherine, Huang, Edmund, Husain, Syed A., Jackson, Annette M., Kers, Jesper, Kikić, Željko, Klein, Amanda, Kozakowski, Nicolas, Liapis, Helen, Mangiola, Massima, Montgomery, Robert A., Nankinvell, Brian, Neil, Desley A.H., Nickerson, Peter, Rabant, Marion, Randhawa, Parmjeet, Riella, Leonardo V., Rosales, Ivy, Royal, Virginie, Sapir-Pichhadze, Ruth, Sarder, Pinaki, Sarwal, Minnie, Schinstock, Carrie, Stegall, Mark, Solez, Kim, van der Laak, Jeroen, Wiebe, Chris, Colvin, Robert B., Loupy, Alexandre, Mengel, Michael, Roufosse, Candice, Naesens, Maarten, Haas, Mark, Lefaucheur, Carmen, Mannon, Roslyn B., Afrouzian, Marjan, Alachkar, Nada, Aubert, Olivier, Bagnasco, Serena M., Batal, Ibrahim, Bellamy, Chris O.C., Broecker, Verena, Budde, Klemens, Clahsen-Van Groningen, Marian, Coley, Shana M., Cornell, Lynn D., Dadhania, Darshana, Demetris, Anthony J., Einecke, Gunilla, Farris, Alton B., Fogo, Agnes B., Friedewald, John, Gibson, Ian W., Horsfield, Catherine, Huang, Edmund, Husain, Syed A., Jackson, Annette M., Kers, Jesper, Kikić, Željko, Klein, Amanda, Kozakowski, Nicolas, Liapis, Helen, Mangiola, Massima, Montgomery, Robert A., Nankinvell, Brian, Neil, Desley A.H., Nickerson, Peter, Rabant, Marion, Randhawa, Parmjeet, Riella, Leonardo V., Rosales, Ivy, Royal, Virginie, Sapir-Pichhadze, Ruth, Sarder, Pinaki, Sarwal, Minnie, Schinstock, Carrie, Stegall, Mark, Solez, Kim, van der Laak, Jeroen, Wiebe, Chris, Colvin, Robert B., Loupy, Alexandre, and Mengel, Michael
- Abstract
The XVIth Banff Meeting for Allograft Pathology was held in Banff, Alberta, Canada, from September 19 to 23, 2022, as a joint meeting with the Canadian Society of Transplantation. In addition to a key focus on the impact of microvascular inflammation and biopsy-based transcript analysis on the Banff Classification, further sessions were devoted to other aspects of kidney transplant pathology, in particular T cell–mediated rejection, activity and chronicity indices, digital pathology, xenotransplantation, clinical trials, and surrogate endpoints. Although the output of these sessions has not led to any changes in the classification, the key role of Banff Working Groups in phrasing unanswered questions, and coordinating and disseminating results of investigations addressing these unanswered questions was emphasized. This paper summarizes the key Banff Meeting 2022 sessions not covered in the Banff Kidney Meeting 2022 Report paper and also provides an update on other Banff Working Group activities relevant to kidney allografts.
- Published
- 2024
35. Intragraft gene expression in native kidney BK virus nephropathy versus T cell–mediated rejection: Prospects for molecular diagnosis and risk prediction
- Author
-
Adam, Benjamin A., Kikic, Zeljko, Wagner, Siegfried, Bouatou, Yassine, Gueguen, Juliette, Drieux, Fanny, Reid, Graeme, Du, Katie, Bräsen, Jan H., D’Agati, Vivette D., Drachenberg, Cinthia B., Farkash, Evan A., Brad Farris, Alton, Geldenhuys, Laurette, Loupy, Alexandre, Nickeleit, Volker, Rabant, Marion, Randhawa, Parmjeet, Regele, Heinz, and Mengel, Michael
- Published
- 2020
- Full Text
- View/download PDF
36. The XVth Banff Conference on Allograft Pathology the Banff Workshop Heart Report: Improving the diagnostic yield from endomyocardial biopsies and Quilty effect revisited
- Author
-
Duong Van Huyen, Jean-Paul, Fedrigo, Marny, Fishbein, Gregory A., Leone, Ornella, Neil, Desley, Marboe, Charles, Peyster, Eliot, von der Thüsen, Jan, Loupy, Alexandre, Mengel, Michael, Revelo, Monica P., Adam, Benjamin, Bruneval, Patrick, Angelini, Annalisa, Miller, Dylan V., and Berry, Gerald J.
- Published
- 2020
- Full Text
- View/download PDF
37. COVID-19-related medical research: a meta-research and critical appraisal
- Author
-
Marc Raynaud, Huanxi Zhang, Kevin Louis, Valentin Goutaudier, Jiali Wang, Quentin Dubourg, Yongcheng Wei, Zeynep Demir, Charlotte Debiais, Olivier Aubert, Yassine Bouatou, Carmen Lefaucheur, Patricia Jabre, Longshan Liu, Changxi Wang, Xavier Jouven, Peter Reese, Jean-Philippe Empana, and Alexandre Loupy
- Subjects
COVID-19 ,Systematic review ,Critical appraisal ,Quality of research ,Medicine (General) ,R5-920 - Abstract
Abstract Background Since the start of the COVID-19 outbreak, a large number of COVID-19-related papers have been published. However, concerns about the risk of expedited science have been raised. We aimed at reviewing and categorizing COVID-19-related medical research and to critically appraise peer-reviewed original articles. Methods The data sources were Pubmed, Cochrane COVID-19 register study, arXiv, medRxiv and bioRxiv, from 01/11/2019 to 01/05/2020. Peer-reviewed and preprints publications related to COVID-19 were included, written in English or Chinese. No limitations were placed on study design. Reviewers screened and categorized studies according to i) publication type, ii) country of publication, and iii) topics covered. Original articles were critically appraised using validated quality assessment tools. Results Among the 11,452 publications identified, 10,516 met the inclusion criteria, among which 7468 (71.0%) were peer-reviewed articles. Among these, 4190 publications (56.1%) did not include any data or analytics (comprising expert opinion pieces). Overall, the most represented topics were infectious disease (n = 2326, 22.1%), epidemiology (n = 1802, 17.1%), and global health (n = 1602, 15.2%). The top five publishing countries were China (25.8%), United States (22.3%), United Kingdom (8.8%), Italy (8.1%) and India (3.4%). The dynamic of publication showed that the exponential growth of COVID-19 peer-reviewed articles was mainly driven by publications without original data (mean 261.5 articles ± 51.1 per week) as compared with original articles (mean of 69.3 ± 22.3 articles per week). Original articles including patient data accounted for 713 (9.5%) of peer-reviewed studies. A total of 576 original articles (80.8%) showed intermediate to high risk of bias. Last, except for simulation studies that mainly used large-scale open data, the median number of patients enrolled was of 102 (IQR = 37–337). Conclusions Since the beginning of the COVID-19 pandemic, the majority of research is composed by publications without original data. Peer-reviewed original articles with data showed a high risk of bias and included a limited number of patients. Together, these findings underscore the urgent need to strike a balance between the velocity and quality of research, and to cautiously consider medical information and clinical applicability in a pressing, pandemic context. Systematic review registration https://osf.io/5zjyx/
- Published
- 2021
- Full Text
- View/download PDF
38. In situ multiplex immunofluorescence analysis of the inflammatory burden in kidney allograft rejection: A new tool to characterize the alloimmune response
- Author
-
Calvani, Julien, Terada, Megumi, Lesaffre, Corinne, Eloudzeri, Maëva, Lamarthée, Baptiste, Burger, Carole, Tinel, Claire, Anglicheau, Dany, Vermorel, Agathe, Couzi, Lionel, Loupy, Alexandre, Duong Van Huyen, Jean-Paul, Bruneval, Patrick, and Rabant, Marion
- Published
- 2020
- Full Text
- View/download PDF
39. COVID-19-related medical research: a meta-research and critical appraisal
- Author
-
Raynaud, Marc, Zhang, Huanxi, Louis, Kevin, Goutaudier, Valentin, Wang, Jiali, Dubourg, Quentin, Wei, Yongcheng, Demir, Zeynep, Debiais, Charlotte, Aubert, Olivier, Bouatou, Yassine, Lefaucheur, Carmen, Jabre, Patricia, Liu, Longshan, Wang, Changxi, Jouven, Xavier, Reese, Peter, Empana, Jean-Philippe, and Loupy, Alexandre
- Published
- 2021
- Full Text
- View/download PDF
40. COVID-19 pandemic and worldwide organ transplantation: a population-based study
- Author
-
Olivier Aubert, MD, Daniel Yoo, MPH, Dina Zielinski, PhD, Emanuele Cozzi, MD, Massimo Cardillo, MD, Michael Dürr, MD, Beatriz Domínguez-Gil, MD, Elisabeth Coll, MD, Margarida Ivo Da Silva, MD, Ville Sallinen, MD, Karl Lemström, MD, Karsten Midtvedt, MD, Camilo Ulloa, MD, Franz Immer, MD, Annemarie Weissenbacher, MD, Natalie Vallant, MD, Nikolina Basic-Jukic, MD, Kazunari Tanabe, MD, Georgios Papatheodoridis, PhD, Georgia Menoudakou, MSc, Martin Torres, MD, Carlos Soratti, MD, Daniela Hansen Krogh, Carmen Lefaucheur, MD, Gustavo Ferreira, MD, Helio Tedesco Silva, Jr, MD, David Hartell, MA, John Forsythe, MD, Lisa Mumford, MSc, Peter P Reese, MD, François Kerbaul, MD, Christian Jacquelinet, MD, Serge Vogelaar, MD, Vassilios Papalois, MD, and Alexandre Loupy, MD
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
Summary: Background: Preliminary data suggest that COVID-19 has reduced access to solid organ transplantation. However, the global consequences of the COVID-19 pandemic on transplantation rates and the effect on waitlisted patients have not been reported. We aimed to assess the effect of the COVID-19 pandemic on transplantation and investigate if the pandemic was associated with heterogeneous adaptation in terms of organ transplantation, with ensuing consequences for waitlisted patients. Methods: In this population-based, observational, before-and-after study, we collected and validated nationwide cohorts of consecutive kidney, liver, lung, and heart transplants from 22 countries. Data were collected from Jan 1 to Dec 31, 2020, along with data from the same period in 2019. The analysis was done from the onset of the 100th cumulative COVID-19 case through to Dec 31, 2020. We assessed the effect of the pandemic on the worldwide organ transplantation rate and the disparity in transplant numbers within each country. We estimated the number of waitlisted patient life-years lost due to the negative effects of the pandemic. The study is registered with ClinicalTrials.gov, NCT04416256. Findings: Transplant activity in all countries studied showed an overall decrease during the pandemic. Kidney transplantation was the most affected, followed by lung, liver, and heart. We identified three organ transplant rate patterns, as follows: countries with a sharp decrease in transplantation rate with a low COVID-19-related death rate; countries with a moderate decrease in transplantation rate with a moderate COVID-19-related death rate; and countries with a slight decrease in transplantation rate despite a high COVID-19-related death rate. Temporal trends revealed a marked worldwide reduction in transplant activity during the first 3 months of the pandemic, with losses stabilising after June, 2020, but decreasing again from October to December, 2020. The overall reduction in transplants during the observation time period translated to 48 239 waitlisted patient life-years lost. Interpretation: We quantified the impact of the COVID-19 pandemic on worldwide organ transplantation activity and revealed heterogeneous adaptation in terms of organ transplantation, both at national levels and within countries, with detrimental consequences for waitlisted patients. Understanding how different countries and health-care systems responded to COVID-19-related challenges could facilitate improved pandemic preparedness, notably, how to safely maintain transplant programmes, both with immediate and non-immediate life-saving potential, to prevent loss of patient life-years. Funding: French national research agency (INSERM) ATIP Avenir and Fondation Bettencourt Schueller.
- Published
- 2021
- Full Text
- View/download PDF
41. An automated histological classification system for precision diagnostics of kidney allografts
- Author
-
Daniel Yoo, Valentin Goutaudier, Gillian Divard, Juliette Gueguen, Brad C. Astor, Olivier Aubert, Marc Raynaud, Zeynep Demir, Julien Hogan, Patricia Weng, Jodi Smith, Rouba Garro, Bradley A. Warady, Rima S. Zahr, Marta Sablik, Katherine Twombley, Lionel Couzi, Thierry Berney, Olivia Boyer, Jean-Paul Duong-Van-Huyen, Magali Giral, Alaa Alsadi, Pierre A. Gourraud, Emmanuel Morelon, Moglie Le Quintrec, Sophie Brouard, Christophe Legendre, Dany Anglicheau, Jean Villard, Weixiong Zhong, Nassim Kamar, Oriol Bestard, Arjang Djamali, Klemens Budde, Mark Haas, Carmen Lefaucheur, Marion Rabant, and Alexandre Loupy
- Subjects
General Medicine ,General Biochemistry, Genetics and Molecular Biology - Published
- 2023
42. Modeling graft loss in patients with donor-specific antibody at baseline using the Birmingham-Mayo (BirMay) predictor: Implications for clinical trials
- Author
-
Bentall, Andrew, Smith, Byron H., Gonzales, Manuel Moreno, Bonner, Keisha, Park, Walter D., Cornell, Lynn D., Dean, Patrick G., Schinstock, Carrie A., Borrows, Richard, Lefaucheur, Carmen, Loupy, Alexandre, and Stegall, Mark D.
- Published
- 2019
- Full Text
- View/download PDF
43. Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell–mediated rejection
- Author
-
Bouatou, Yassine, Viglietti, Denis, Pievani, Daniele, Louis, Kevin, Duong Van Huyen, Jean-Paul, Rabant, Marion, Aubert, Olivier, Taupin, Jean-Luc, Glotz, Denis, Legendre, Christophe, Loupy, Alexandre, and Lefaucheur, Carmen
- Published
- 2019
- Full Text
- View/download PDF
44. Value of monitoring circulating donor-reactive memory B cells to characterize antibody-mediated rejection after kidney transplantation
- Author
-
Luque, Sergi, Lúcia, Marc, Melilli, Edoardo, Lefaucheur, Carmen, Crespo, Marta, Loupy, Alex, Bernal-Casas, David, Gomà, Montse, Jarque, Marta, Crespo, Elena, Montero, Núria, Manonelles, Anna, Cruzado, Josep M., Gil-Vernet, Salvador, Grinyó, Josep M., and Bestard, Oriol
- Published
- 2019
- Full Text
- View/download PDF
45. A phase I/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients
- Author
-
Jordan, Stanley C., Choi, Jua, Aubert, Olivier, Haas, Mark, Loupy, Alexandre, Huang, Edmund, Peng, Alice, Kim, Irene, Louie, Sabrina, Ammerman, Noriko, Najjar, Reiad, Puliyanda, Dechu, and Vo, Ashley
- Published
- 2018
- Full Text
- View/download PDF
46. Banff Digital Pathology Working Group: Image Bank, Artificial Intelligence Algorithm, and Challenge Trial Developments
- Author
-
Farris, Alton B., primary, Alexander, Mariam P., additional, Balis, Ulysses G. J., additional, Barisoni, Laura, additional, Boor, Peter, additional, Bülow, Roman D., additional, Cornell, Lynn D., additional, Demetris, Anthony J., additional, Farkash, Evan, additional, Hermsen, Meyke, additional, Hogan, Julien, additional, Kain, Renate, additional, Kers, Jesper, additional, Kong, Jun, additional, Levenson, Richard M., additional, Loupy, Alexandre, additional, Naesens, Maarten, additional, Sarder, Pinaki, additional, Tomaszewski, John E., additional, van der Laak, Jeroen, additional, van Midden, Dominique, additional, Yagi, Yukako, additional, and Solez, Kim, additional
- Published
- 2023
- Full Text
- View/download PDF
47. Complement-activating donor-specific anti-HLA antibodies in solid organ transplantation: systematic review, meta-analysis, and critical appraisal
- Author
-
Al-Awadhi, Solaf, primary, Raynaud, Marc, additional, Louis, Kevin, additional, Bouquegneau, Antoine, additional, Taupin, Jean-Luc, additional, Aubert, Olivier, additional, Loupy, Alexandre, additional, and Lefaucheur, Carmen, additional
- Published
- 2023
- Full Text
- View/download PDF
48. Report of the 2022 Banff Heart Concurrent: Focus on Non-HLA Antibodies in Rejection and the Pathology of “Mixed” Rejection
- Author
-
Fedrigo, Marny, primary, Berry, Gerald J., additional, Coutance, Guillaume, additional, Reed, Elaine F., additional, Lin, Chieh-Yu, additional, Giarraputo, Alessia, additional, Kransdorf, Evan, additional, Thaunat, Olivier, additional, Goddard, Martin, additional, Angelini, Annalisa, additional, Neil, Desley AH., additional, Bruneval, Patrick, additional, Duong Van Huyen, Jean-Paul, additional, Loupy, Alexandre, additional, and Miller, Dylan V., additional
- Published
- 2023
- Full Text
- View/download PDF
49. The Banff 2022 Kidney Meeting Report: Re-Appraisal of Microvascular Inflammation and the Role of Biopsy-Based Transcript Diagnostics
- Author
-
Naesens, Maarten, primary, Roufosse, Candice, additional, Haas, Mark, additional, Lefaucheur, Carmen, additional, Mannon, Roslyn B., additional, Adam, Benjamin A., additional, Aubert, Olivier, additional, Böhmig, Georg A., additional, Callemeyn, Jasper, additional, Groningen, Marian Clahsen-van, additional, Cornell, Lynn D., additional, Demetris, Anthony J., additional, Drachenberg, Cinthia B., additional, Einecke, Gunilla, additional, Fogo, Agnes B., additional, Gibson, Ian W., additional, Halloran, Philip, additional, Hidalgo, Luis G., additional, Horsfield, Catherine, additional, Huang, Edmund, additional, Kikić, Željko, additional, Kozakowski, Nicolas, additional, Nankivell, Brian, additional, Rabant, Marion, additional, Randhawa, Parmjeet, additional, Riella, Leonardo V., additional, Sapir-Pichhadze, Ruth, additional, Schinstock, Carrie, additional, Solez, Kim, additional, Tambur, Anat R., additional, Thaunat, Olivier, additional, Wiebe, Chris, additional, Zielinski, Dina, additional, Colvin, Robert, additional, Loupy, Alexandre, additional, and Mengel, Michael, additional
- Published
- 2023
- Full Text
- View/download PDF
50. Validation of a prediction system for risk of kidney allograft failure in pediatric kidney transplant recipients: An international observational study
- Author
-
Hogan, Julien, primary, Divard, Gillian, additional, Aubert, Olivier, additional, Garro, Rouba, additional, Boyer, Olivia, additional, Donald Cooper, Lee Alex, additional, Farris, Alton Brad, additional, Fila, Marc, additional, Seifert, Michael, additional, Sellier-Leclerc, Anne-Laure, additional, Smith, Jody, additional, Fichtner, Alexander, additional, Tönshoff, Burkhard, additional, Twombley, Katherine, additional, Warady, Bradley, additional, Pearl, Meghan, additional, Zahr, Rima S., additional, Lefaucheur, Carmen, additional, Patzer, Rachel, additional, and Loupy, Alexandre, additional
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.